Find a Trial

Trial Summary

Protocol No.CTO-LOXO-IDH-20002
Principal InvestigatorTurk, Anita
PhasePhase I
Age GroupAdult
TitleA Phase 1 Study of LY3410738 Administered to Patients with Advanced Solid Tumors with IDH1 Mutations
DescriptionThis is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Evidence of IDH1 R132 mutation in tumor tissue (any solid tumor) or circulating tumor DNA (cholangiocarcinoma, chondrosarcoma, and glioma) as determined by molecular testing routinely performed at a CLIA, ISO/IEC, CAP, or other similarly certified laboratory.
  • Histologically or cytologically confirmed diagnosis of advanced or metastatic cholangiocarcinoma, not eligible for curative resection.
For a full list of participation criteria, please visit
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632